Anzeige
Mehr »
Login
Dienstag, 12.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Die KI-Revolution ist der Super-Megatrend, der Anleger reich machen kann
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AKB9 | ISIN: DK0060738599 | Ticker-Symbol: WDH1
Tradegate
11.11.24
08:00 Uhr
35,420 Euro
-0,420
-1,17 %
1-Jahres-Chart
DEMANT A/S Chart 1 Jahr
5-Tage-Chart
DEMANT A/S 5-Tage-Chart
RealtimeGeldBriefZeit
35,66035,96011.11.
35,72035,94011.11.
GlobeNewswire (Europe)
196 Leser
Artikel bewerten:
(1)

Demant A/S: Demant A/S: Revised financial outlook for 2024 and preliminary H1 financial key figures

Finanznachrichten News

16.7.2024 18:44:28 CEST | Demant A/S | Inside information

Company announcement no 2024-10 16 July 2024

Revised financial outlook for 2024 and preliminary H1 financial key figures

Outlook for 2024 revised: Organic growth of 2-4% (prev. 4-8%) and EBIT before special items of DKK 4,300-4,600 million (prev. DKK 4,600-5,000 million)

Preliminary organic growth of 3% in Q2 below expectations due to Hearing Aids and Diagnostics

Current low growth in Hearing Aids expected to continue in H2 due to our chosen managed care brand strategy in the US

Developments during the period

Unless otherwise indicated, the commentary below relates to H1 2024.

Today, Demant updates its financial outlook for 2024 and provides preliminary financial key figures for H1, with the Group reporting organic growth of 3% (Q2: 3%) and an EBIT before special items of DKK 2,068 million for H1 2024. In addition, the Group has seen very solid free cash flow generation in the reporting period.

  • In Hearing Aids, organic growth in revenue from external customers was 2% (Q2: 1%) driven by very strong comparative figures, but the development in Q2 has nonetheless been below expectations. In the reporting period, the reception of our flagship product Oticon Intent by the independent channel has been good and in line with our expectations.
    • Following our strategic decision to position our brands across channels in the US more clearly, we have seen significant loss of market share in managed care in Q2, which has not been fully compensated by additional sales to independents in the US. Despite the current headwinds, we remain firmly committed to our brand strategy in the US.
    • The general competitive environment remains intense, which has had some impact on growth - particularly in more price-focused channels and segments.
  • In Diagnostics, organic growth was 3% (Q2: 0%) with negative growth in China and across our portfolio of balance products. While performance was weaker than expected, we expect growth to improve in H2.
  • Hearing Care saw positive performance with organic growth of 3% (Q2: 5%), which is in line with expectations.

Revised financial outlook for 2024

We have revised our financial outlook for 2024 based on an updated view on H2 and the results realised in Q2:

Metric

Outlook for 2024

Organic growth

2-4% (previously 4-8%)

EBIT before special items

DKK 4,300-4,600 million (previously DKK 4,600-5,000 million)

Share buy-backs

Remain unchanged at more than DKK 2,000 million

The revised outlook is based on the following updated assumptions:

  • In Hearing Aids, the loss of market share in managed care and the lack of ability to fully compensate through additional sales to independents in the US are assumed to continue at the current level for the remainder of 2024.
  • In order to achieve a better balance between revenue and OPEX growth, we have taken certain cost-saving initiatives across the Group. When including the effect of these initiatives, we expect OPEX to grow organically in the low-to-mid single digits in H2 compared to the same period last year.

Publication of Interim Report

The stated financial key figures are preliminary, and Demant will release the full details in its Interim Report to be published on 14 August 2024.

Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300

www.demant.com

Other contacts:

René Schneider, CFO

Peter Pudselykke, Head of Investor Relations

Trine Kromann-Mikkelsen, VP Corporate Communication and Sustainability

Contacts

  • Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com

About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people's health and hear-ing. We create life-changing differences through hearing health.

© 2024 GlobeNewswire (Europe)
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.